The NCI-H226 cell line, often abbreviated as H226, is a human cancer cell line derived from a patient with malignant pleural mesothelioma. Malignant pleural mesothelioma is a rare and aggressive form of cancer that develops in the pleura, the thin layer of tissue that covers the lungs and lines the chest cavity. This type of cancer is often associated with asbestos exposure.
The H226 cell line is frequently used in cancer research, particularly in the study of mesothelioma biology, drug resistance, and the development of novel therapeutic strategies.
Researchers use the H226 cell line for various purposes, such as:
- Investigating the molecular mechanisms underlying mesothelioma development and progression.
- Studying the cellular response to chemotherapeutic agents and targeted therapies, as well as developing strategies for overcoming drug resistance.
- Evaluating the efficacy of novel anticancer therapeutics and treatment strategies in vitro before testing them in in vivo models.
- Identifying and validating potential therapeutic targets and biomarkers for mesothelioma.
The use of the H226 cell line, along with other mesothelioma cell lines, has contributed significantly to advancing our understanding of mesothelioma biology and has aided in the development of more effective treatment options for patients.